Expression and significance of VEGF,miR-205and target protein Ezrin and Lamin A/C in ovarian cancer

Journal of Central South University (Medical Sciences)

Volumn 39, Issue 2, 2014, Pages 142-150

  Zhou, Jun ^a,b   Liu, Hailing ^a,b   Chen, Yile ^c   Wen, Jifang ^a,b   Li, Long ^a,b   Wu, Xiaoying ^a,b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

Author keywords

Ezrin; Invasion; Lamin A C; MiR 205; Ovarian cancer; VEGF

Indexed keywords

CYTOSKELETON PROTEIN; EZRIN; LAMIN A; LMNA PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN205 MICRORNA, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

BLOOD; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; OVARY TUMOR; REAL TIME POLYMERASE CHAIN REACTION;

CYTOSKELETAL PROTEINS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LAMIN TYPE A; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896964405     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.11817/j.issn.1672-7347.2014.02.006     Document Type: Article

References (29)

1. CHEN Yabing, YE Dafeng, XIE Xing, et al. Expression of VEGF/ VEGFRs and activation of STATs in ovarian cancer[J]. Chinese Journal of Oncology, 2005,27(1): 33-37.
2. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer[J]. Anticancer Res, 2004,24(3b): 1973-1979. (Pubitemid 38954620)
3. Ueda M, Terai Y, Kumagai K, et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells[J]. Gynecol Oncol, 2001,82(1): 162-166. (Pubitemid 32634970)
4. Yue X, Wang P, Xu J, et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A[J]. Oncol Rep, 2012,27(4): 1200-1206.
5. Wu H, Zhu S, Mo YY, et al. Suppression of cell growth and invasion by miR-205 in breast cancer[J]. Cell Res, 2009,19(4): 439-448.
6. Jennet M, Harvey, Gary M, et al. Estrogen receptor status by immunohistochemistry issuperior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. Am Soc Clin Oncol, 1999,17(5): 1474-1481.
7. Wendner N, Folkman J, Pozza F, et al. Tumor angiogenesis:a new significant and independent prognosis indicator in early-stage breast carcinoma[J]. Natl Cancer Inst, 1992,84(24): 1875-1887. (Pubitemid 23004615)
8. LU Yunping, ZHANG Ali, WANG Shixuan, et al. Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism[J]. Chinese Journal of Obstetrics and Gynecology, 2002, 37(5): 294-297.
9. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma[J], Cancer Res, 1996,56(13): 3004-3009. (Pubitemid 26199745)
10. Gadducci A, Viacava P, COSÍO S, et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma[J]. Anticancer Res, 2003,23(3C): 3001-3008. (Pubitemid 36969852)
11. HA Jianli, ZHANG Zebo. Study on relationship between expression of VEGF and microvascular density in human epithelial ovarian cancer tissue[J]. Journal of Xianning University. Medical Sciences, 2011, 25(4): 296-298.
12. Lee JS, Kim HS, Jung JJ, et al. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression[J]. Gynecol Oncol, 2002,85(3): 469-475. (Pubitemid 34651887)
13. Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of Epithelial- mesen-chymal transition [J]. Cell Cycle, 2008,7(20): 3112-3118.
14. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer[J]. Cancer Res, 2007,67(18): 8699-8707. (Pubitemid 47437445)
15. Wu B, Li J, Huang D, et al. Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells[J]. BMC Cancer, 2011,11:527.
16. Zhong ZQ, Song MM, He Y, et al. Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro[J]. Asian Pac J Cancer Prev,2012,13(8): 3781-3789.
17. Mak H, Naba A, Varma S, et al. Ezrin phosphorylation on tyrosine 477 regulates invasion and metastasis of breast cancer cells [J]. BMC Cancer, 2012,12: 82.
18. Wang HJ, Zhu JS, Zhang Q, et al. High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy [J]. World J Gastroenterol, 2009,15(16): 2016-2019.
19. Yasuoka H, Tsujimoto M, Inagaki M, et al. Clinicopathological significance of podocalyxin and phosphorylated Ezrin in uterine endometrioid adenocarcinoma[J].J Clin Pathol, 2012,65(5): 399-402.
20. Gao W, Zhang C, Feng Y, et al. Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma [J]. PLoS One, 2012, 7(11): e50710.
21. Valdman A, Fang X, Pang ST, et al. Ezrin expression in prostate cancer and benign prostatic tissue[J], Eur Urol, 2005,48(5): 852-857.
22. Endo K, Kondo S, Shackleford J, et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration[J]. Oncogene, 2009, 28(14): 1725-1735.
23. Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients[J]. Gynecol Oncol; 2003,90(2): 273-281. (Pubitemid 36952014)
24. Agrelo R, Setien F, Espada J, et al. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma[J].J Clin Oncol, 2005,23(17): 3940-3947. (Pubitemid 46218697)
25. Willis ND, Cox TR, Rahman-Casans SF, et al. Lamin A/C is a risk biomarker in colorectal cancer[J]. PLoS One, 2008,3(8): e2988.
26. Debes JD, Sebo TJ, Heemers HV, et al. p300 modulates nuclear morphology in prostate cancer[J]. Cancer Res, 2005,65(3): 708-712. (Pubitemid 40216426)
27. Machiels BM, Broers JL, Raymond Y, et al. Abnormal A-type lamin organiza-tion in a human lung carcinoma cell line[J]. Eur J Cell Biol, 1995,67(4): 328-335.
28. Wu Z, Wu L, Weng D, et al. Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma[J]. J Exp Clin Cancer Res, 2009,28: 8.
29. LI Zexia. The role of miR-205 mediated VEGF promoting invasion of human ovarian cancer cell [D], Changsha: Central South University, 2012.